Lyra Therapeutics reports results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in the treatment of chronic rhinosinusitis (CRS) ($4.93, 0.00)
Nanobiotix presents full results from the completed Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer (€3.05, 0.00)
Tarsus Pharmaceuticals to present four data sets at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting ($48.51, 0.00)
FDA updates label for Bristol Myers Squibb's CAMZYOS ($49.23, 0.00)
Bristol Myers Squibb Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for adult patients with symptomatic NYHA class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) did not meet its dual primary endpoints ($51.34, 0.00)
Nanobiotix doses first patient in new randomized Phase 2 study evaluating JNJ-1900 (NBTXR3) for patients with stage 3 unresectable Non-Small Cell Lung cancer (€3.04, 0.00)
NMPA accepts submission of Grand Pharmaceutical Group's NDA for TP-03 for Demodex blepharitis (HK$4.67, 0.00)
Nanobiotix announces completion of phase 1 study of NBTXR3 (JNJ-1900) in pancreatic cancer
Lyra Therapeutics fully enrolls pivotal Phase 3 ENLIGHTEN 2 trial of LYR-210 for the treatment of chronic rhinosinusitis ($0.22, 0.00)
Bristol Myers Squibb presents new long-term follow-up results from MAVA-LTE study of CAMZYOS ($49.95, 0.00)
Powered by FactSet Research Systems Inc.